Kristen Ciombor
Last active: 9/9/2013

Profile

Education and Training/Academic Appointments

1997-2001    A.B. cum laude, Biochemical Sciences, Harvard University, Cambridge, MA

2001-2005    M.D., University of Miami Miller School of Medicine, Miami, FL

2005-2008    Intern and Resident, Department of Internal Medicine, University of Miami/Jackson Memorial Hospital/Miami Veterans Administration, Miami, FL

2008-2009    Chief Resident, Department of Internal Medicine, University of Miami/Jackson Memorial Hospital/Miami Veterans Administration, Miami, FL

2009-2013    Fellow, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN

2011-2013    M.S., Clinical Investigation, Vanderbilt University, Nashville, TN

2013-present Assistant Professor of Internal Medicine, Division of Medical Oncology, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Professional Associations

American Society of Clinical Oncology

American Association for Cancer Research

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Current therapy and future directions in biliary tract malignancies. Ciombor KK, Goff LW (2013) Curr Treat Options Oncol 14(3): 337-49
    › Primary publication · 23686724 (PubMed) · PMC3769474 (PubMed Central)
  2. Aflibercept. Ciombor KK, Berlin J, Chan E (2013) Clin Cancer Res 19(8): 1920-5
    › Primary publication · 23444216 (PubMed) · PMC3710732 (PubMed Central)
  3. Advances in the management of biliary tract cancers. Ciombor KK, Goff LW (2013) Clin Adv Hematol Oncol 11(1): 28-34
    › Primary publication · 23416860 (PubMed) · PMC3713630 (PubMed Central)
  4. Transfusion medicine illustrated. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis. Gehrie E, Neff AT, Ciombor KK, Harris N, Seegmiller AC, Young PP (2012) Transfusion 52(1): 4-5
    › Primary publication · 22032241 (PubMed)
  5. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM (2012) Am J Clin Oncol 35(5): 446-50
    › Primary publication · 21552097 (PubMed)
  6. Management of small cell lung cancer. Ciombor KK, Rocha Lima CM (2006) Curr Treat Options Oncol 7(1): 59-68
    › Primary publication · 16343369 (PubMed)
  7. Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation. Martin KA, Schalm SS, Romanelli A, Keon KL, Blenis J (2001) J Biol Chem 276(11): 7892-8
    › Primary publication · 11108720 (PubMed)
  8. Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway. Martin KA, Schalm SS, Richardson C, Romanelli A, Keon KL, Blenis J (2001) J Biol Chem 276(11): 7884-91
    › Primary publication · 11108711 (PubMed)